Human Herpes Virus-8 and Other Risk Factors for Kaposi's Sarcoma in Kidney Transplant Recipients1

Farge, Dominique; Lebbe, Célèste; Marjanovic, Zora; Tuppin, Philippe; Mouquet, C.; Péraldi, Marie-Noëlle; Lang, Philippe; Hiesse, C; Antoine, Corinne; Legendre, Christophe; Bedrossian, J; Gagnadoux, M. F.; Loirat, Chantal; Pellet, Claire; Sheldon, Julie; Golmard, Jean‐Louis; Agbalika, F.; Schulz, Thomas F.

doi:10.1097/00007890-199905150-00007

Cited by 112 publications

(84 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,13,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] In particular, PT-KS was primarily observed in kidney recipients ( Figure 1A), whereas lower PT-KS incidences have been recorded in patients receiving other SOTs, mainly liver and heart. PT-KS usually occurs rather early after transplantation (median interval, 30 months), usually as cutaneous or mucosal lesions, whereas visceral involvement occurs in 25%-50% of the cases.…”

Section: Posttransplantation Ks Pel and MCDmentioning

confidence: 99%

How I treat HHV8/KSHV-related diseases in posttransplant patients

Riva¹,

Luppi²,

Barozzi³

et al. 2012

Blood

View full text Add to dashboard Cite

Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and sometimes fatal, neoplastic, and nonneoplastic diseases. HHV8-related clinical manifestations notably range from Kaposi sarcoma (KS) to either primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and peripheral cytopenias, associated or not with hemophagocytic syndromes, and to acute hepatitis syndromes. We reviewed the patient series reported in the literature and summarized clinical management aspects, in terms of diagnosis, follow-up, and treatment. We described typical clinical presentations and histopathologic diagnostic features of these diseases, and we discussed the role of HHV8-specific serologic, molecular, and immunologic assays, particularly focusing on recent data from HHV8-specific T-cell monitoring in posttransplantation KS patients. We finally discussed actual therapeutic options, namely, the reduction or discontinuation of immunosuppressive therapy or the switch from calcineurin inhibitors to mTOR inhibitors, as alternatives to antineoplastic chemotherapy, along with the use of antiherpesvirus agents as prophylactic or therapeutic measures, and treatment with rituximab in posttransplantation multicentric Castleman disease patients and non-neoplastic HHV8-associated syndromes. IntroductionHerpesvirus-associated hematologic diseases often represent primary clinical challenges during the multidisciplinary follow-up of posttransplant patients, either with hematopoietic stem cell transplant (HSCT) or with solid organ transplant (SOT). In immunosuppressed organ recipients, latent human ␥-herpesvirus, namely, EBV and human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) are typically responsible for several virus-driven neoplastic proliferations, as well as they may sometimes cause uncommon, but equally life-threatening, non-neoplastic infectious complications. During the past decade, large amounts of experimental evidence have come out on these topics, and some of them have yet begun to influence the clinical behavior, in terms of diagnosis and treatment. Chiefly, EBV-related complications have been extensively studied and discussed, so that now physicians can rely on accurate and updated clinical recommendations, in particular dealing with early diagnosis, monitoring and treatment of EBV ϩ posttransplantation lymphoproliferative diseases (PTLDs). 1 With regards to HHV8, practical management of the virus-associated neoplastic lymphoproliferations has deeply been revised in HIVpositive subjects, 2,3 whereas in SOT and HSCT settings, the diagnostic and therapeutic issues about the various HHV8-driven manifestations (either neoplastic or non-neoplastic) are only occasionally reported in the literature, but most of these diseases revealed to be rapidly lethal if not timely recognized and adequately treated. Indeed, posttra...

show abstract

Section: Posttransplantation Ks Pel and MCDmentioning

confidence: 99%

How I treat HHV8/KSHV-related diseases in posttransplant patients

Riva¹,

Luppi²,

Barozzi³

et al. 2012

Blood

View full text Add to dashboard Cite

show abstract

“…HHV-8 has also been associated with two forms of lymphoproliferative disorders: body cavity-based lymphomas and multicentric Castleman's disease (12,34). Several studies of HHV-8 infections in solid organ (liver, lung, heart, and kidney) transplant recipients have been reported previously (2,3,11,16,18,(22)(23)(24)27; C. Frances, C. Mouquet, and V. Calvez, Letter to the editor, N. Engl. J. Med.…”

mentioning

confidence: 99%

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…These patients failed to show at least partial regression of the neoplasia, except one patient in whom Kaposi's sarcoma was diagnosed in the autopsy. In all the patients with Kaposi's sarcoma, a polymerase chain reaction (PCR) assay detected HHV-8 DNA in histological sections (29). In our study, two patients were diagnosed with Kaposi's sarcoma and both were HHV-8 positive.…”

Section: Discussionmentioning

confidence: 57%

Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey

Karakoyun¹,

Onen²,

Baran³

et al. 2018

Turk J Gastroenterol

View full text Add to dashboard Cite

Results: In the study group, de novo cancer was diagnosed in 13 of the 206 patients. Post-transplant lymphoproliferative disease (PTLD) occurred in seven (53.8%) patients and other malignancies in six of the 13 patients. The types of PTLD were as follows: B-cell origin (n=2), Epstein-Barr virus (EBV)-related (n=2), T-cell origin (n=1), and Hodgkin's lymphoma (n=2). EBV DNA was isolated from seven patients, three of whom developed PTLD. The others developed

show abstract

Human Herpes Virus-8 and Other Risk Factors for Kaposi's Sarcoma in Kidney Transplant Recipients1

Cited by 112 publications

References 32 publications

How I treat HHV8/KSHV-related diseases in posttransplant patients

How I treat HHV8/KSHV-related diseases in posttransplant patients

Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients

Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey

Contact Info

Product

Resources

About